Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...
Milestone Pharmaceuticals provides 2025 corporate outlook
Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal ...
H.C. Wainwright maintains $25 target on Milestone shares
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and a price target of $25.00 on Milestone Pharmaceuticals, traded on NASDAQ under the ticker (NASDAQ:MIST). The stock has shown strong ...
Medscape27d
ECG Abnormalities and Stroke Incidence
paroxysmal AF, autonomic dysfunction, inflammation No trials yet Left-ventricular Hypertrophy 1–18% 8% by MRI among people aged 45–84 years 36–41% among hypertensives 1.5- to 3-fold increase ...